Highlights
- Cogstate Limited (ASX:CGS) generated US$60.9 million in FY26 revenue, up 15%.
- New FY26 sales contracts totalled US$89.0 million, increasing 116% year-on-year.
- September-quarter FY27 net sales contracts reached US$25.1 million.
- Contracted FY27 Revenue rose to US$56.8 million by September 30, 2026.
Cogstate Limited provides digital cognitive assessments, clinical trial measurement services and neuroscience expertise to biopharmaceutical researchers and healthcare organisations. Shares in Cogstate (ASX:CGS) traded at AUD 3.595 on November 17, 2026, up 0.70% during the session. The company entered FY27 following higher annual revenue and new contract activity, while its September-quarter update highlighted additional trial awards and a growing amount of contracted revenue scheduled for future periods.
Cognitive Testing and Clinical Trial Services
Cogstate supports pharmaceutical and biotechnology companies testing treatments for conditions affecting the central nervous system. Its services combine digital cognitive tests, clinician-administered assessments, rater Training and monitoring of data quality. These capabilities are designed to help sponsors evaluate changes in cognition and other clinical outcomes during trials. The company also offers cognitive assessment technology for healthcare settings.
Its work covers Alzheimer’s disease, psychiatry, sleep disorders, rare diseases and other neurological indications. Cogstate (ASX:CGS) operates through Clinical Trials and Healthcare revenue streams, with the clinical trials Business accounting for most FY26 revenue. Its international network of scientific specialists and trained clinicians supports research programmes across multiple markets. In some studies, central rating allows calibrated clinicians to conduct assessments remotely, rather than relying exclusively on individual trial sites.
Contract Expansion and September-Quarter Developments
In FY26, Cogstate executed US$89.0 million in net new sales contracts, compared with US$41.3 million in FY25. The company reported 90 new clinical trial starts during FY26, against 35 a year earlier, and 171 active trials compared with 110. Its annual investor briefing also identified a broader mix of therapeutic indications: 77% of FY26 new contract value originated outside Alzheimer’s disease.
The latest quarterly update showed Cogstate (ASX:CGS) signed US$25.13 million of net sales contracts in the three months ended September 30, 2026, compared with US$21.42 million in the corresponding quarter. Nine new clinical trials were added, including four Phase 2 and four Phase 3 studies. Management highlighted awards in bipolar disorder and depression and a continuing contribution from channel partners.
Contracted revenue scheduled for recognition in FY27 increased from US$48.3 million at June 30 to US$56.8 million at September 30. Total contracted future revenue reached US$143.7 million, compared with US$101.8 million a year earlier. The company noted that the in-year revenue contribution from new contracts was affected by the proportion of longer-duration Phase 3 trials and a lower mix of licence fees.
FY26 Financial Results and Operating Economics
For the financial year ended June 30, 2026, Cogstate (ASX:CGS) reported revenue of US$60.9 million, up from US$53.1 million in FY25. Clinical Trials revenue was US$58.4 million, while Healthcare revenue was approximately US$2.5 million. Group Gross Profit increased to US$35.4 million from US$32.4 million, although the gross Margin declined to 58% from 61%. The results therefore reflected higher activity alongside changes in service mix and delivery costs.
Earnings before interest, tax, Depreciation and Amortisation rose to US$18.3 million from US$16.0 million. Profit before tax increased to US$16.1 million from US$13.9 million, while net profit after tax reached US$11.9 million compared with US$10.1 million. Operating Cash Flow was US$8.5 million for FY26. The company reported US$34.8 million in cash and no Debt in its FY26 investor briefing; management subsequently discussed the effect of receivables timing on cash conversion.
Technology Investment and FY27 Outlook
Cogstate is developing AI-enabled rater training and central monitoring tools as part of its plans to increase the efficiency of regulated trial workflows. Its FY26 investor materials outlined increased Capital Expenditure during FY27 and FY28 for a technology-enabled operating platform. The company expects revenue growth in FY27, although the outcome depends on the timing and value of new contract wins and the portion recognised as revenue during the year.
Management indicated that, subject to contract execution and revenue conversion, it expected to maintain the FY26 annual EBITDA margin despite planned investment. It also anticipated a greater financial contribution from the June 2027 half-year than from the December 2026 half-year. These are management expectations rather than reported FY27 outcomes.
Risks and Near-Term Monitoring Points
Clinical trial cancellations, delays in sponsor programmes and the timing of contract commencement can affect revenue recognition. Changes in the mix between software licence income and service delivery may also influence gross margins. Cogstate faces execution requirements associated with clinician capacity, data quality, partner integration and increased technology spending. FY26 cash flow was lower than profit after tax, making subsequent collections and working-capital movements relevant to monitoring.
For Cogstate (ASX:CGS), upcoming December-half financial results will offer further evidence on how the contracted revenue pipeline converts into recognised sales. New contract wins, central rating adoption, software-related income, cash receipts and spending on AI-enabled workflows will provide additional operating measures.
Key Insights
Cogstate (ASX:CGS) began FY27 with a larger contracted revenue base following growth in FY26 sales, trial starts and earnings. September-quarter contract awards added to that pipeline, while longer trial durations affected near-term recognition. Future reporting will clarify the relationship between new business, service mix, cash generation and technology investment.






Please wait processing your request...